Endo International plc Interest Expense 2011-2026 | ENDP

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Endo International plc

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	350 M	562 M	533 M	539 M	522 M	1.31 M	338 K	-63.7 M	32.3 M	53.1 M	621 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
562 M	-63.7 M	230 M

Quarterly Interest Expense Endo International plc

2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
10 K	120 K	109 K	-	74.8 M	140 M	135 M	-	143 M	142 M	134 M	-	136 M	129 M	133 M	-	137 M	135 M	133 M	-	837 K	3.95 M	1 M	-	808 K	1.78 M	2.04 M	-	2.87 M	-5.18 M	1.91 M	-	-506 K	-24.5 M	12 M	-	5.72 M	6.6 M	6.41 M	-	14.7 M	16.7 M	18.3 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
143 M	-24.5 M	49.6 M

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	4.92 K	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.2	0.42 %	$ 129 M	Canada
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Emergent BioSolutions EBS	87.9 M	$ 12.84	2.8 %	$ 657 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	13 M	$ 21.5	-0.12 %	$ 2.05 B	France
Evolus EOLS	127 K	$ 6.03	-10.27 %	$ 374 M	USA
Harrow Health HROW	21.3 M	$ 54.06	8.3 %	$ 1.76 B	USA
Jupiter Wellness JUPW	-5.37 M	-	-	$ 33.6 M	USA
China Pharma Holdings CPHI	27.4 K	$ 1.23	1.65 %	$ 21.5 M	China
Bausch Health Companies BHC	-28 M	$ 7.51	4.16 %	$ 2.74 B	Canada
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Cumberland Pharmaceuticals CPIX	606 K	$ 3.95	-0.77 %	$ 55.5 M	USA
Organogenesis Holdings ORGO	20 K	$ 4.36	-5.93 %	$ 574 M	USA
Sundial Growers SNDL	81 K	$ 1.72	-1.41 %	$ 3.37 M	Canada
Pacira BioSciences PCRX	-373 K	$ 25.21	3.07 %	$ 1.17 B	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 3.73	2.46 %	$ 4.63 M	USA
Rockwell Medical RMTI	2.3 M	$ 0.98	13.92 %	$ 22.9 M	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
Perrigo Company plc PRGO	900 K	$ 14.36	3.42 %	$ 1.97 B	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Veru VERU	862 K	$ 2.28	0.58 %	$ 308 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
cbdMD YCBD	-29.5 K	$ 1.11	-4.31 %	$ 4.79 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 4.11	-6.06 %	$ 124 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	2.78 M	$ 9.62	5.25 %	$ 683 M	USA
Solid Biosciences SLDB	652 K	$ 5.33	-2.14 %	$ 218 M	USA
SCYNEXIS SCYX	3.13 M	$ 0.64	-0.03 %	$ 30.6 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
Tilray TLRY	46.6 M	$ 9.43	-3.03 %	$ 5.83 B	Canada
TherapeuticsMD TXMD	300 K	$ 1.79	8.78 %	$ 18.7 M	USA
Zomedica Corp. ZOM	175 K	-	-0.21 %	$ 98 M	USA